Efficacy of bosentan in the treatment of Raynaud’s phenomenon in patients with systemic sclerosis never treated with prostanoids
The objective of this study was to evaluate the efficacy of the endothelin receptor antagonist, bosentan, in patients with Raynaud’s phenomenon secondary to systemic sclerosis never treated with prostanoids and without digital ulcers. The study design is a preliminary, prospective open label trial....
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2014-03-01
|
Series: | Reumatismo |
Subjects: | |
Online Access: | http://www.reumatismo.org/index.php/reuma/article/view/691 |
id |
doaj-19ee1325f6c94695a984b80106d3b49a |
---|---|
record_format |
Article |
spelling |
doaj-19ee1325f6c94695a984b80106d3b49a2020-11-24T20:58:21ZengPAGEPress PublicationsReumatismo0048-74492240-26832014-03-0165628629110.4081/reumatismo.2013.691629Efficacy of bosentan in the treatment of Raynaud’s phenomenon in patients with systemic sclerosis never treated with prostanoidsS. Parisi0M. Bruzzone1C. Centanaro Di Vittorio2A. Laganà3C.L. Peroni4E. Fusaro5Struttura Complessa di Reumatologia, A.O. Città della Salute e della Scienza di TorinoStruttura Complessa di Reumatologia, A.O. Città della Salute e della Scienza di TorinoStruttura Complessa di Reumatologia, A.O. Città della Salute e della Scienza di TorinoStruttura Complessa di Reumatologia, A.O. Città della Salute e della Scienza di TorinoStruttura Complessa di Reumatologia, A.O. Città della Salute e della Scienza di TorinoStruttura Complessa di Reumatologia, A.O. Città della Salute e della Scienza di TorinoThe objective of this study was to evaluate the efficacy of the endothelin receptor antagonist, bosentan, in patients with Raynaud’s phenomenon secondary to systemic sclerosis never treated with prostanoids and without digital ulcers. The study design is a preliminary, prospective open label trial. The patients recruited took one 62.5 mg dose of bosentan twice daily for 4 weeks, followed by 125 mg twice daily for 24 weeks. Of the 10 patients recruited, all completed the study. The reduction in Raynaud’s phenomenon attacks at week 24 from the baseline was statistically significant (Δ-1.3, P=0.0126). The Raynaud’s condition score showed a statistically significant improvement (Δ-1.4, P=0.0279), as did the visual analog pain scale (Δ-1.5, P=0.0016) at the 24<sup>th</sup> week. Bosentan appears to be effective and may be a valid alternative for the treatment of severe secondary Raynaud’s phenomenon for patients where prostanoids therapy is contraindicated or refused.http://www.reumatismo.org/index.php/reuma/article/view/691Systemic sclerosis, Raynaud’s phenomenon, Endothelin receptor antagonist, Bosentan, Raynaud’s condition score. |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
S. Parisi M. Bruzzone C. Centanaro Di Vittorio A. Laganà C.L. Peroni E. Fusaro |
spellingShingle |
S. Parisi M. Bruzzone C. Centanaro Di Vittorio A. Laganà C.L. Peroni E. Fusaro Efficacy of bosentan in the treatment of Raynaud’s phenomenon in patients with systemic sclerosis never treated with prostanoids Reumatismo Systemic sclerosis, Raynaud’s phenomenon, Endothelin receptor antagonist, Bosentan, Raynaud’s condition score. |
author_facet |
S. Parisi M. Bruzzone C. Centanaro Di Vittorio A. Laganà C.L. Peroni E. Fusaro |
author_sort |
S. Parisi |
title |
Efficacy of bosentan in the treatment of Raynaud’s phenomenon in patients with systemic sclerosis never treated with prostanoids |
title_short |
Efficacy of bosentan in the treatment of Raynaud’s phenomenon in patients with systemic sclerosis never treated with prostanoids |
title_full |
Efficacy of bosentan in the treatment of Raynaud’s phenomenon in patients with systemic sclerosis never treated with prostanoids |
title_fullStr |
Efficacy of bosentan in the treatment of Raynaud’s phenomenon in patients with systemic sclerosis never treated with prostanoids |
title_full_unstemmed |
Efficacy of bosentan in the treatment of Raynaud’s phenomenon in patients with systemic sclerosis never treated with prostanoids |
title_sort |
efficacy of bosentan in the treatment of raynaud’s phenomenon in patients with systemic sclerosis never treated with prostanoids |
publisher |
PAGEPress Publications |
series |
Reumatismo |
issn |
0048-7449 2240-2683 |
publishDate |
2014-03-01 |
description |
The objective of this study was to evaluate the efficacy of the endothelin receptor antagonist, bosentan, in patients with Raynaud’s phenomenon secondary to systemic sclerosis never treated with prostanoids and without digital ulcers. The study design is a preliminary, prospective open label trial. The patients recruited took one 62.5 mg dose of bosentan twice daily for 4 weeks, followed by 125 mg twice daily for 24 weeks. Of the 10 patients recruited, all completed the study. The reduction in Raynaud’s phenomenon attacks at week 24 from the baseline was statistically significant (Δ-1.3, P=0.0126). The Raynaud’s condition score showed a statistically significant improvement (Δ-1.4, P=0.0279), as did the visual analog pain scale (Δ-1.5, P=0.0016) at the 24<sup>th</sup> week. Bosentan appears to be effective and may be a valid alternative for the treatment of severe secondary Raynaud’s phenomenon for patients where prostanoids therapy is contraindicated or refused. |
topic |
Systemic sclerosis, Raynaud’s phenomenon, Endothelin receptor antagonist, Bosentan, Raynaud’s condition score. |
url |
http://www.reumatismo.org/index.php/reuma/article/view/691 |
work_keys_str_mv |
AT sparisi efficacyofbosentaninthetreatmentofraynaudsphenomenoninpatientswithsystemicsclerosisnevertreatedwithprostanoids AT mbruzzone efficacyofbosentaninthetreatmentofraynaudsphenomenoninpatientswithsystemicsclerosisnevertreatedwithprostanoids AT ccentanarodivittorio efficacyofbosentaninthetreatmentofraynaudsphenomenoninpatientswithsystemicsclerosisnevertreatedwithprostanoids AT alagana efficacyofbosentaninthetreatmentofraynaudsphenomenoninpatientswithsystemicsclerosisnevertreatedwithprostanoids AT clperoni efficacyofbosentaninthetreatmentofraynaudsphenomenoninpatientswithsystemicsclerosisnevertreatedwithprostanoids AT efusaro efficacyofbosentaninthetreatmentofraynaudsphenomenoninpatientswithsystemicsclerosisnevertreatedwithprostanoids |
_version_ |
1716786125640564736 |